These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23745990)

  • 1. TAK1 inhibition in the DFG-out conformation.
    Kilty I; Green MP; Bell AS; Brown DG; Dodd PG; Hewson C; Hughes SJ; Phillips C; Ryckmans T; Smith RT; van Hoorn WP; Cohen P; Jones LH
    Chem Biol Drug Des; 2013 Nov; 82(5):500-5. PubMed ID: 23745990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAK1 selective inhibition: state of the art and future opportunities.
    Kilty I; Jones LH
    Future Med Chem; 2015; 7(1):23-33. PubMed ID: 25582331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
    Ziegler K; Hauser DR; Unger A; Albrecht W; Laufer SA
    ChemMedChem; 2009 Nov; 4(11):1939-48. PubMed ID: 19731280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2010 May; 20(9):2765-9. PubMed ID: 20378346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors.
    Sabatini S; Manfroni G; Barreca ML; Bauer SM; Gargaro M; Cannalire R; Astolfi A; Brea J; Vacca C; Pirro M; Massari S; Tabarrini O; Loza MI; Fallarino F; Laufer SA; Cecchetti V
    Chem Biol Drug Des; 2015 Oct; 86(4):531-45. PubMed ID: 25589097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD).
    Muraoka T; Ide M; Irie M; Morikami K; Miura T; Nishihara M; Kashiwagi H
    Chem Pharm Bull (Tokyo); 2016; 64(11):1622-1629. PubMed ID: 27803473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors.
    Dorn A; Schattel V; Laufer S
    Bioorg Med Chem Lett; 2010 May; 20(10):3074-7. PubMed ID: 20418099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors.
    Kulkarni RG; Laufer S; Mangannavar C; Garlapati A
    Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts.
    Gu J; Liu X; Wang QX; Tan HW; Guo M; Jiang WF; Zhou L
    Exp Cell Res; 2012 Oct; 318(16):2105-15. PubMed ID: 22749815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAK1 contributes to the enhanced responsiveness of LTB(4)-treated neutrophils to Toll-like receptor ligands.
    Gaudreault É; Paquet-Bouchard C; Fiola S; Le Bel M; Lacerte P; Shio MT; Olivier M; Gosselin J
    Int Immunol; 2012 Nov; 24(11):693-704. PubMed ID: 22843747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
    Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
    Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
    Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
    Badrinarayan P; Sastry GN
    J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.